Tiantian Tan

ORCID: 0000-0003-0676-3706
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nanoparticle-Based Drug Delivery
  • RNA Interference and Gene Delivery
  • Nanoplatforms for cancer theranostics
  • Cancer Research and Treatments
  • MicroRNA in disease regulation
  • Extracellular vesicles in disease
  • Advancements in Battery Materials
  • Immunotherapy and Immune Responses
  • Proteoglycans and glycosaminoglycans research
  • Systemic Lupus Erythematosus Research
  • Gold and Silver Nanoparticles Synthesis and Applications
  • Advanced biosensing and bioanalysis techniques
  • Magnolia and Illicium research
  • Quantum Dots Synthesis And Properties
  • Glioma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Biological and pharmacological studies of plants
  • Autoimmune and Inflammatory Disorders Research
  • Electrochemical sensors and biosensors
  • Curcumin's Biomedical Applications
  • Pharmacological Effects of Natural Compounds
  • Glycosylation and Glycoproteins Research
  • Teratomas and Epidermoid Cysts
  • Supercapacitor Materials and Fabrication
  • Bioactive Compounds and Antitumor Agents

Hangzhou Normal University
2020-2023

Sichuan University
2016-2021

Chengdu University of Traditional Chinese Medicine
2021

Zhejiang Medicine (China)
2021

Chengdu Medical College
2021

Ping An (China)
2021

Guangdong Pharmaceutical University
2021

Chengdu University
2019

Abstract Background In the current treatment of non-small cell lung cancer (NSCLC), traditional chemotherapy causes high toxicity, so it is necessary to develop safe chemical drug delivery vehicles clinically. Chemotherapy monotherapy prone resistance. combined with other therapies such as nucleic acid drugs an effective way avoid resistance and toxicity continuous chemotherapy. this study, siRNA therapy were treat paclitaxel-resistant NSCLC in order increase efficacy reduce toxicity. This...

10.1186/s12645-023-00194-7 article EN cc-by Cancer Nanotechnology 2023-07-29

Abstract Background Effective treatment of glioma requires a nanocarrier that can cross the blood–brain barrier (BBB) to target tumor lesion. In current study, elemene (ELE) and cabazitaxel (CTX) liposomes were prepared by conjugating with transferrin (Tf) embedding cell membrane proteins RG2 cells into (active-targeting biomimetic liposomes, Tf-ELE/CTX@BLIP), which exhibited effective BBB infiltration glioma. Results The findings showed Tf-ELE/CTX@BLIP was highly stable. significant...

10.1186/s12951-021-01048-3 article EN cc-by Journal of Nanobiotechnology 2021-09-26

Chondroitin sulfate-mediated albumin corona nanoparticles were readily prepared without any chemical reaction, and their active tumor targeting therapeutic effects examined. Negatively charged chondroitin sulfate (CS) positively doxorubicin (DOX) self-assembled into (CS-DOX-NPs) via electrostatic interactions. Bovine serum (BSA) was then adsorbed on the surface of CS-DOX-NPs to form (BC-DOX-NPs) protected from endogenous proteins. Due dual effect BSA CS, BC-DOX-NPs interacted with gp60,...

10.1016/j.ajps.2021.03.004 article EN cc-by-nc-nd Asian Journal of Pharmaceutical Sciences 2021-04-21

Chemotherapeutic agents trigger antitumor immune response through inducing immunogenic tumor cell death. However, severe toxicity to system and insufficient death hinder chemotherapy from arousing efficient immunity in vivo. In this study, the cytotoxic drug, pirarubicin (THP), was entrapped into nanostructured lipid carriers (NLC); THP-NLC significantly reduced of THP improved status breast cancer bearing mice. When coinjected with iRGD (a tumor-penetrating peptide), drug accumulation...

10.1021/acs.molpharmaceut.6b00932 article EN Molecular Pharmaceutics 2016-11-28

Biomimetic design has been extensively investigated. The only FDA-approved biomimetic albumin-bound paclitaxel may not be beneficial to some treated patients due rapid dissociation upon intravenous infusion and no substantial improvement in the drug's pharmacokinetics or biodistribution. Herein, we developed an alternative injectable preformed anticancer drug delivery. We combined HSA, Kolliphor HS 15 (HS15), pirarubicin (THP) via purely physical forces a thin-film hydration method obtain...

10.1021/acsami.9b11307 article EN ACS Applied Materials & Interfaces 2019-09-03

It is necessary to discover a novel antitumor liposome with prolonged circulation time, high efficacy, and low cost. Here, we reported liposomal honokiol (HNK) prepared new type of excipient, Kolliphor HS15, which was termed as HS15-LP-HNK. In addition, employed PEGylated (PEG-LP-HNK) positive control. The HS15-LP-HNK by thin-film hydration method. near-spherical morphology an average size 80.62 ± 0.72 nm (PDI = 0.234 0.007) mean zeta potential -3.91 0.06 mv. vivo studies exhibited no...

10.1080/03639045.2018.1506475 article EN Drug Development and Industrial Pharmacy 2018-07-30

We have formulated 7-ethyl-10-hydroxy camptothecin (SN38) nanocrystals using a novel combination of reversible reactions and pharmaceutical technology. The are taken up more efficiently by cells accumulate in tumors than the commercially available compound irinotecan (CPT-11), leading to superior anti-tumor efficacy vitro vivo.

10.1039/c8cc10191d article EN Chemical Communications 2019-01-01

10.1136/jnnp.34.1.104-a article EN Journal of Neurology Neurosurgery & Psychiatry 1971-02-01

Abstract Efficient chemotherapy for glioma demands a nanocarrier that can overcome the blood-brain barrier (BBB) and then target tumor location. Elemene (ELE) cabazitaxel (CTX) liposomes are prepared by conjugating with transferrin (Tf) embedding cell membrane proteins of RG2 into (active-targeting biomimetic liposomes, Tf-ELE/CTX@BLIP), which demonstrated resultful in infiltrating BBB targeting glioma, respectively. Tf-ELE/CTX@BLIP is highly stable, displaying prominent peculiarity...

10.21203/rs.3.rs-717860/v1 preprint EN cc-by Research Square (Research Square) 2021-07-21
Coming Soon ...